Market Research Logo

Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015

Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2015’, provides an overview of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Recurrent Head And Neck Cancer Squamous Cell Carcinoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Recurrent Head and Neck Cancer Squamous Cell Carcinoma Overview
Therapeutics Development
Pipeline Products for Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Overview
Pipeline Products for Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Comparative Analysis
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development
Advaxis, Inc.
Amgen Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
Daiichi Sankyo Company, Limited
Genentech, Inc.
Glycotope GmbH
Immunovative Therapies, Ltd.
Laboratoires Pierre Fabre SA
Mabion SA
MedImmune, LLC
Merck & Co., Inc.
Novartis AG
Oncolytics Biotech Inc.
Ono Pharmaceutical Co., Ltd.
Panacea Biotec Limited
PCI Biotech AS
Shionogi & Co., Ltd.
Symphogen A/S
Threshold Pharmaceuticals, Inc.
VentiRx Pharmaceuticals, Inc.
Recurrent Head and Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AdIL-24 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AlloVax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
alpelisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
axalimogene filolisbac - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-5069 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-9150 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bleomycin sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cetuximab biobetter - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cetuximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cetuximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cetuximab biosimilar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COTI-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
duligotuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
durvalumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
durvalumab + tremelimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
elgemtumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ficlatuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
futuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
motolimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
patritumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pelareorep - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-488210 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tarloxotinib bromide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vinflunine ditartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones
Featured News & Press Releases
Aug 27, 2015: Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide in Patients With Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2015
Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd...1)
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd...1)
Products under Development by Companies, H2 2015 (Contd...2)
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Advaxis, Inc., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AstraZeneca Plc, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Critical Outcome Technologies Inc., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genentech, Inc., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Glycotope GmbH, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Immunovative Therapies, Ltd., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Laboratoires Pierre Fabre SA, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mabion SA, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncolytics Biotech Inc., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Symphogen A/S, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Threshold Pharmaceuticals, Inc., H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2015
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report